German and Canadian Organizations Partner to Develop 3D Printed Contractile Tissue

Share this Article

It’s been a big week for bioprinting, with news of planned 3D printed organs coming from both Prellis Biologics and BIOLIFE4D. The bioprinting world is one that doesn’t slow down, and a new research collaboration between multiple major players in the field is set to continue advances. Canadian company Aspect Biosystems is partnering with German InSCREENeX as well as the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) to develop 3D printed contractile tissue for pharmaceutical testing. The collaboration is being supported by the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) and the Federal Ministry for Economic Affairs and Energy’s Central Innovation Program for SMEs (ZIM).

Aspect Biosystems is known for its Lab-on-a-Printer technology, which consists of a series of modular microfluidic printhead cartridges created for tissue design. Using coaxial flow focusing, a cell-laden biological fiber is generated within the cartridge and printed into a 3D structure. The technology was used to create the company’s 3D BioRing platform, a platform of 3D printed muscle tissue that contracts and relaxes like real muscle tissue. 3D BioRing can be applied to multiple types of contractile tissue; one example is the 3DBioRing Airway, which allows researchers to study bronchoconstriction and relaxation in an in vitro setting.

[Image: Aspect Biosystems]

“We are excited to work with high profile international partners with unique technologies like InSCREENeX and Fraunhofer ITEM to expand the applications of our 3DBioRing muscle tissue platform and develop models of other tissues including blood vessels, heart, and lung,” said Tamer Mohamed, President and CEO of Aspect Biosystems. “Ultimately, this collaboration will enable us to apply our Lab-on-a-Printer bioprinting technology to create novel tissues that can be used to improve the reliability of pre-clinical toxicity testing and could lead to the development of improved therapeutics for a host of vascular, cardiac, and respiratory diseases.”

InSCREENeX is a spinoff company of the Helmholtz Center for Infection Research. It provides genetically engineered cell systems for drug discovery and development, and offers two main product lines: SCREENflex and CI-SCREEN.

“Personalized in vitro test systems that recreate the disease in a dish will take future drug development and regenerative medicine approaches to the next level,” said Dr. Tobias May, CEO of InSCREENeX. “Aspect Biosystems’ bioprinting technology is at the forefront to develop three dimensional tissue with unmatched in-vivo like functionality. By partnering with Aspect Biosystems and Fraunhofer ITEM, and with the support from ZIM and IRAP, we will join forces to develop unique personalized cell systems. These expandable and physiologically relevant cell systems will be used as building blocks to bioprint contractile tissues with unparalleled physiology. This combined approach leads to an easy scalable and consistent production process for bioprinting in vitro tissues of highest quality in unlimited quantity.”

Fraunhofer ITEM conducts independent research projects as well as funded public projects and contract research. Its focus is on translational disease models, diagnostic techniques and innovative therapy, and its research areas range from toxicology and consumer protection to non-clinical and clinical drug research and development and safety testing.

“Valid preclinical testing of new therapeutic drugs requires predictive and available test systems,” said Dr. Armin Braun, Division Director, Preclinical Pharmacology and in vitro Toxicology. “Three-dimensional bioprinting enables the generation of human and physiological functional tissue in almost unlimited quantities and in standardized quality. These test systems will confirm that Aspect’s bioprinted tissues are optimised as reliable preclinical tools to identify the toxicity and efficacy of experimental therapeutics.”

Discuss this story and other 3D printing topics at 3DPB.com, or share your thoughts below.

 

Facebook Comments

Share this Article


Recent News

Combining Over-3D Printing of Continuous Carbon Fiber Reinforced Composites with Stamp Forming Organo-sheet Substrates

3D Printing News Briefs: July 19, 2019



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

3D Printing News Briefs: July 2nd, 2019

We’re talking partnerships and materials in today’s 3D Printing News Briefs. The Alfa Romeo F1 team and Additive Industries are strengthening their technology partnership, while Beam-IT and SLM Solutions are...

Premium AEROTEC Partnering with Lockheed Martin to Search for 3D Printing Opportunities on the F-35

The Paris Air Show ended over a week ago, but event news from the 3D printing industry continues to fly in as we hear about more investment and partnership announcements. The...

New Balance and Formlabs Launch TripleCell 3D Printing Platform and Rebound Resin for Athletic Shoes

While I’m not much for recreational jogging these days, I’ll always remember my first real running shoes – a pair of dark gray Sauconys, which I got to pick out...

Carbon and Arkema’s Sartomer Subsidiary Partner to Increase Materials Performance & Digital Manufacturing Adoption

Four years ago, specialty chemical and advanced materials developer Arkema announced that it would increase its focus on 3D printing materials research; this was followed two years later by a major investment...


Shop

View our broad assortment of in house and third party products.


Print Services

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our 3DPrint.com.

You have Successfully Subscribed!